Skip to contentS
Sigyn Therapeutics, Inc.
S
SIGYSigyn Therapeutics, Inc. Q1 2021 · 10-Q
Revenue—
Net Income-$461.68K-$461.68KN/M vs Q1 2020 EPS Diluted-$0.01-$0.01N/M vs Q1 2020 Operating Income-$402,096N/M Operating Cash Flow-$274,424N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
Free Cash Flowderived-$277,295— ended Mar 31, 2021 · filed May 17, 2021 · 47 d after period end